ALMIRALL, S.A. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.49 EUR | +1.25% |
|
+3.91% | +0.83% |
| Mar. 13 | Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment | MT |
| Feb. 19 | Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... |  |
| Sales 2024 * | 971M 1.04B | Sales 2025 * | 1.07B 1.14B | Capitalization | 1.76B 1.88B |
|---|---|---|---|---|---|
| Net income 2024 * | 26M 27.78M | Net income 2025 * | 63M 67.3M | EV / Sales 2024 * | 1.7 x |
| Net cash position 2024 * | 100M 107M | Net cash position 2025 * | 132M 141M | EV / Sales 2025 * | 1.52 x |
| P/E ratio 2024 * |
81.5
x | P/E ratio 2025 * |
29.2
x | Employees | 1,904 |
| Yield 2024 * |
2.23% | Yield 2025 * |
2.25% | Free-Float | 34.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Almirall, S.A.
More press releases
More news
| 1 day | +1.25% | ||
| 1 week | +3.91% | ||
| Current month | +2.78% | ||
| 1 month | +5.59% | ||
| 3 months | -3.63% | ||
| 6 months | -3.68% | ||
| Current year | +0.83% |
1 week
8.11
8.51
1 month
7.988.51
Current year
7.859.30
1 year
7.1610.08
3 years
7.1615.35
5 years
7.1618.50
10 years
7.1619.36
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 14-07-24 | |
| Director of Finance/CFO | 54 | 19-11-10 | |
Karl Ziegelbauer
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 81 | 07-05-28 | |
Seth J. Orlow
BRD | Director/Board Member | - | 15-12-31 |
Eva-Lotta Allan
BRD | Director/Board Member | 65 | 20-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 8.495 | +1.31% | 88 255 |
| 24-04-24 | 8.385 | +0.30% | 111,551 |
| 24-04-23 | 8.36 | +1.46% | 131,086 |
| 24-04-22 | 8.24 | 0.00% | 135,752 |
| 24-04-19 | 8.24 | +0.80% | 105,986 |
Delayed Quote BME, April 25, 2024 at 09:10 am EDT
More quotes
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Sector
Pharmaceuticals
Calendar
2024-05-10
- Annual General Meeting - First Call
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
8.385
EUR
Average target price
11.28
EUR
Spread / Average Target
+34.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.83% | 1.88B | |
| +22.98% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.17% | 219B | |
| +6.35% | 199B | |
| -9.90% | 196B | |
| -8.75% | 149B | |
| -5.21% | 146B |
- Stock Market
- Equities
- ALM Stock
